Corrections:

Yunu Jung^1,*, Jinbong Park^2,*, Hye-Lin Kim², Dong-Hyun Youn¹, JongWook Kang¹, Seona Lim¹, Mi-Young Jeong², Gautam Sethi³, Sung-Joo Park⁴, Kwang Seok Ahn² and Jae-Young Um^1,2

¹ Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Dongdaemun-Gu, Seoul 02447, Republic of Korea
² Basic Research Laboratory for Comorbidity Regulation, College of Korean Medicine, Kyung Hee University, Dongdaemun- Gu, Seoul 02447, Republic of Korea
³ Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore
⁴ Department of Herbology, College of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 54538, Republic of Korea
^* These authors have contributed equally to this work

Published: July 16, 2019

This article has been corrected: Due to errors in image processing, an IHC staining slide of ER in Figure 4 was used twice by mistake. The proper Figure 4 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:87194-87208. DOI: https://doi.org/10.18632/oncotarget.19909.

Figure 4: Immunohistochemical analysis of AR, ERα and SRC1 in the prostate tissues of TP-induced BPH rats. Representative photomicrographs of the immunohistochemically stained prostate tissues (upper panels, magnification ×400) and relative density of the positively immunostained area (lower panels) of AR, ERα and SRC1 of each group. Values are the mean ± S.D. of the data from three or more separate experiments. ^#P < 0.05 when compared to B; ^*P < 0.05 when compared to C. B, normal control group; C, TP-induced BPH group; VA, VA-treated BPH group; Fi, Fi-treated BPH group.